What was the overall valuation of the US vaccine adjuvants market in 2024?

The overall market valuation was $375.2 Million in 2024. Read More

What is the projected market valuation for the US vaccine adjuvants market by 2035?

The projected valuation for 2035 is $472.6 Million. Read More

What is the expected CAGR for the US vaccine adjuvants market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 2.12%. Read More

Which companies are considered key players in the US vaccine adjuvants market?

Key players include GlaxoSmithKline, Novartis, Sanofi, Merck & Co., Pfizer, AstraZeneca, Bristol-Myers Squibb, Bayer, and Seppic. Read More

What are the main types of adjuvants used in the US vaccine adjuvants market?

Main types include Alum, Monophosphoryl Lipid A, TLR Agonists, Saponins, and Liposomes. Read More

What was the market value of Alum in the US vaccine adjuvants market in 2024?

The market value of Alum was $100 Million in 2024. Read More

How much is the market for Liposomes projected to grow by 2035?

The market for Liposomes is projected to grow from $120.2 Million in 2024 to $162.6 Million by 2035. Read More

What applications are driving the US vaccine adjuvants market?

Applications driving the market include Infectious Diseases, Cancer, Autoimmune Diseases, and Allergies. Read More

What was the market value for Infectious Diseases in 2024?

The market value for Infectious Diseases was $150 Million in 2024. Read More

What is the projected market value for Contract Manufacturing Organizations by 2035?

The projected market value for Contract Manufacturing Organizations is expected to rise from $125.2 Million in 2024 to $162.6 Million by 2035. Read More

US Vaccine Adjuvants Market

ID: MRFR/Pharma/14018-HCR

100 Pages

Nidhi Mandole

Last Updated: April 24, 2026

US Vaccine Adjuvants Market Research Report: Size, Share, Trend Analysis By Types (Pathogen Component, Particulate Adjuvants, Others), By Route of Administration (Oral, Intramuscular, Subcutaneous, Intradermal) and By End Users (Pediatric, Adult) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Alum
  2. 4.1.2 Monophosphoryl Lipid A
  3. 4.1.3 TLR Agonists
  4. 4.1.4 Saponins
  5. 4.1.5 Liposomes
2. 4.2 Pharmaceutical, BY Application (USD Million)
  1. 4.2.1 Infectious Diseases
  2. 4.2.2 Cancer
  3. 4.2.3 Autoimmune Diseases
  4. 4.2.4 Allergies
3. 4.3 Pharmaceutical, BY Route of Administration (USD Million)
  1. 4.3.1 Intramuscular
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Intradermal
  4. 4.3.4 Oral
4. 4.4 Pharmaceutical, BY End Use (USD Million)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Research Institutions
  3. 4.4.3 Contract Manufacturing Organizations
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bayer (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Seppic (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY END USE
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US US Vaccine Adjuvants Market Segmentation

US Vaccine Adjuvants Market By Type (USD Million, 2025-2035)

Alum
Monophosphoryl Lipid A
TLR Agonists
Saponins
Liposomes

US Vaccine Adjuvants Market By Application (USD Million, 2025-2035)

Infectious Diseases
Cancer
Autoimmune Diseases
Allergies

US Vaccine Adjuvants Market By Route of Administration (USD Million, 2025-2035)

Intramuscular
Subcutaneous
Intradermal
Oral

US Vaccine Adjuvants Market By End Use (USD Million, 2025-2035)

US Vaccine Adjuvants Market Companies
Research Institutions
Contract Manufacturing Organizations

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”